Since David Loew took over as CEO in July 2020, Ipsen SA has been one of the most active drugmakers on the business development front and the French company's appetite for deals shows no signs of abating.
Business Development Remains Top Priority For Ipsen
Posts Solid Q4 Results Despite Somatuline Decline
CEO David Loew tells Scrip that Ipsen’s prodigious dealmaking over the past couple of years is set to continue, on top of the acquisition of Albireo announced last month.
